These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31853652)

  • 1. Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1).
    Wilson H; Pagano G; Yousaf T; Polychronis S; De Micco R; Giordano B; Niccolini F; Politis M
    J Neural Transm (Vienna); 2020 Jan; 127(1):51-59. PubMed ID: 31853652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
    Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
    Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.
    Young CB; Cholerton B; Smith AM; Shahid-Besanti M; Abdelnour C; Mormino EC; Hu SC; Chung KA; Peterson A; Rosenthal L; Pantelyat A; Dawson TM; Quinn J; Zabetian CP; Montine TJ; Poston KL
    Neurology; 2024 Jul; 103(2):e209609. PubMed ID: 38870440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting early cognitive decline in newly-diagnosed Parkinson's patients: A practical model.
    Hogue O; Fernandez HH; Floden DP
    Parkinsonism Relat Disord; 2018 Nov; 56():70-75. PubMed ID: 29936131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
    Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
    Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.
    Liu G; Locascio JJ; Corvol JC; Boot B; Liao Z; Page K; Franco D; Burke K; Jansen IE; Trisini-Lipsanopoulos A; Winder-Rhodes S; Tanner CM; Lang AE; Eberly S; Elbaz A; Brice A; Mangone G; Ravina B; Shoulson I; Cormier-Dequaire F; Heutink P; van Hilten JJ; Barker RA; Williams-Gray CH; Marinus J; Scherzer CR; ; ; ; ; ; ;
    Lancet Neurol; 2017 Aug; 16(8):620-629. PubMed ID: 28629879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2).
    Yousaf T; Pagano G; Niccolini F; Politis M
    J Neurol; 2019 May; 266(5):1203-1210. PubMed ID: 30820739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
    Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF
    Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of liver fibrosis with cognitive decline in Parkinson's disease.
    Zolin A; Zhang C; Ooi H; Sarva H; Kamel H; Parikh NS
    J Clin Neurosci; 2024 Jan; 119():10-16. PubMed ID: 37976909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
    Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
    Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of cognitive impairment in an early stage Parkinson's disease cohort.
    Hu MT; Szewczyk-Królikowski K; Tomlinson P; Nithi K; Rolinski M; Murray C; Talbot K; Ebmeier KP; Mackay CE; Ben-Shlomo Y
    Mov Disord; 2014 Mar; 29(3):351-9. PubMed ID: 24395708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient and Clinician Impressions of Cognitive Impairment in Parkinson's Disease.
    Ngo AB; Smith KM
    J Parkinsons Dis; 2020; 10(4):1695-1698. PubMed ID: 32925096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
    Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
    Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder.
    Chahine LM; Xie SX; Simuni T; Tran B; Postuma R; Amara A; Oertel WH; Iranzo A; Scordia C; Fullard M; Linder C; Purri R; Darin A; Rennert L; Videnovic A; Del Riva P; Weintraub D
    Parkinsonism Relat Disord; 2016 Jun; 27():102-6. PubMed ID: 27010070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease.
    Schulz J; Pagano G; Fernández Bonfante JA; Wilson H; Politis M
    Brain; 2018 May; 141(5):1501-1516. PubMed ID: 29701787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. White matter hyperintensities are not associated with cognitive decline in early Parkinson's disease - The DeNoPa cohort.
    Hanning U; Teuber A; Lang E; Trenkwalder C; Mollenhauer B; Minnerup H
    Parkinsonism Relat Disord; 2019 Dec; 69():61-67. PubMed ID: 31678722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson's disease.
    Szeto JY; Mowszowski L; Gilat M; Walton CC; Naismith SL; Lewis SJ
    Parkinsonism Relat Disord; 2015 Jan; 21(1):31-5. PubMed ID: 25465744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive impairment in patients with Parkinson's disease: A 30-month follow-up study.
    Chen L; Yu C; Zhang N; Liu J; Liu W
    Clin Neurol Neurosurg; 2016 Dec; 151():65-69. PubMed ID: 27816027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting the Cognitive Prodrome of Dementia in Parkinson's Disease.
    De Roy J; Postuma RB; Brillon-Corbeil M; Montplaisir J; Génier Marchand D; Escudier F; Panisset M; Chouinard S; Gagnon JF
    J Parkinsons Dis; 2020; 10(3):1033-1046. PubMed ID: 32310188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
    Santiago JA; Potashkin JA
    PLoS One; 2015; 10(11):e0142582. PubMed ID: 26566043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.